Background: The triglyceride glucose-body mass index (TyG-BMI) is considered to be a reliable surrogate marker of insulin resistance (IR). However, limited evidence exists regarding its association with the severity of coronary artery disease (CAD), particularly in hypertensive patients with different glucose metabolic states, including those with H-type hypertension. This study aimed to investigate the relationship between TyG-BMI and CAD severity across different glucose metabolism conditions.
Methods: This retrospective cohort study included 1537 hypertensive patients who underwent coronary angiography. The TyG-BMI was categorized into tertiles and analyzed using logistic regression models and restricted cubic spline (RCS) models to assess its association with multi-vessel CAD. Receiver operating characteristic (ROC) curves were used to evaluate the predictive value of TyG-BMI in detecting the severity of CAD in different glucose metabolism states, including normal glucose regulation (NGR), pre-diabetes mellitus (Pre-DM), and diabetes mellitus (DM). The above method has also been applied to populations of H-type hypertension patients.
Results: The TyG-BMI was significantly associated with the severity of multi-vessel CAD in hypertensive patients (Odds ratio [OR] 1.043, 95% CI 1.032-1.053). In the diabetic subgroup, after adjusting for risk factors, the risk of multi-vessel CAD in the T3 groups was 3.836-fold (95% CI 1.763-8.347; P = 0.001) higher than in the T1 group, with a non-linear dose-response relationship (P for non-linearity = 0.017). In H-type hypertension patients, the TyG-BMI was also significantly correlated with multi-vessel CAD (OR 5.248, 95% CI 1.821-15.126, P = 0.002) in the DM group. The ROC analysis revealed that TyG-BMI had the highest predictive value for multi-vessel CAD in diabetic patients, with an AUC of 0.720 (95% CI 0.661-0.780, P < 0.001).
Conclusions: The TyG-BMI serves as a robust predictor of CAD severity in hypertensive patients, particularly those with diabetes and H-type hypertension. And the non-linear dose-response relationship between TyG-BMI and multi-vessel CAD in diabetic patients underscores its potential clinical utility. This index could serve as a valuable tool for the early identification of individuals at high risk.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11734521 | PMC |
http://dx.doi.org/10.1186/s13098-024-01568-6 | DOI Listing |
J Clin Med
January 2025
Department of Medicine, Université de Montréal and ECOGENE-21, Chicoutimi, QC G7H 7K9, Canada.
Over the past decades, new treatments and guidelines have been introduced for the screening and management of familial hypercholesterolemia (FH). However, the impact of these medical and scientific advances on the characteristics and burden of coronary lesions over time in FH remains poorly documented. The primary goal of this study is to determine the characteristics of coronary lesions in HeFH patients who underwent coronary angiography within two distinct timeframes: the last five years versus those who had the procedure at the same hospital 25 years earlier.
View Article and Find Full Text PDFDiabetol Metab Syndr
January 2025
Department of Cardiology, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, 430074, Hubei, China.
Background: The triglyceride glucose-body mass index (TyG-BMI) is considered to be a reliable surrogate marker of insulin resistance (IR). However, limited evidence exists regarding its association with the severity of coronary artery disease (CAD), particularly in hypertensive patients with different glucose metabolic states, including those with H-type hypertension. This study aimed to investigate the relationship between TyG-BMI and CAD severity across different glucose metabolism conditions.
View Article and Find Full Text PDFVascular
December 2024
Social Determinant of Health Research Center, Babol University of Medical Science, Babol, Iran.
Objectives: Peripheral arterial disease (PAD) and coronary artery disease (CAD) are major contributors to global morbidity and mortality. Many PAD patients remain asymptomatic for CAD, which often leads to undetected coronary artery involvement. This hidden coronary disease poses significant risks, particularly following peripheral revascularization, as increased cardiac demand can precipitate complications.
View Article and Find Full Text PDFJACC Cardiovasc Interv
October 2024
Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address:
J Cardiovasc Pharmacol
November 2024
Robert M. Berne Cardiovascular Research Center and Department of Medicine, University of Virginia, Charlottesville, VA, United States.
Patients with ST-segment elevation myocardial infarction (STEMI) and complex coronary artery disease (CAD) face a poor prognosis, including increased heart failure (HF) risk. Phase 2 clinical trials of anakinra have shown inhibition of the acute inflammatory response and prevention of HF after STEMI, but data on its effects based on CAD complexity are lacking. We performed a pooled secondary analysis of 139 patients with STEMI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!